GUSB

Summary

GUSB (glucuronidase beta, HGNC:4696) is a protein-coding gene on chromosome 7q11.21, encoding Beta-glucuronidase (P08236). Plays an important role in the degradation of dermatan and keratan sulfates.

This gene encodes a hydrolase that degrades glycosaminoglycans, including heparan sulfate, dermatan sulfate, and chondroitin-4,6-sulfate. The enzyme forms a homotetramer that is localized to the lysosome. Mutations in this gene result in mucopolysaccharidosis type VII. Alternative splicing results in multiple transcript variants. There are many pseudogenes of this locus in the human genome.

Source: NCBI Gene 2990 — RefSeq curated summary.

At a glance

• Gene–disease (curated): mucopolysaccharidosis type 7 (Definitive, ClinGen)
• GWAS associations: 1
• Clinical variants (ClinVar): 771 total — 55 pathogenic, 40 likely-pathogenic
• Phenotypes (HPO): 82
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• Dosage sensitivity (ClinGen): haploinsufficiency autosomal recessive, triplosensitivity no evidence
• MANE Select transcript: NM_000181

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4696
Approved symbol	GUSB
Name	glucuronidase beta
Location	7q11.21
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000169919
Ensembl biotype	protein_coding
OMIM	611499
Entrez	2990

Gene structure

Transcript identifiers

Ensembl transcripts: 49 — 37 protein_coding, 5 protein_coding_CDS_not_defined, 4 retained_intron, 3 nonsense_mediated_decay

ENST00000304895, ENST00000421103, ENST00000430730, ENST00000446111, ENST00000447929, ENST00000461622, ENST00000462371, ENST00000465785, ENST00000466883, ENST00000475316, ENST00000476486, ENST00000478118, ENST00000479038, ENST00000489482, ENST00000864776, ENST00000864777, ENST00000864778, ENST00000864779, ENST00000864780, ENST00000864781, ENST00000864782, ENST00000864783, ENST00000864784, ENST00000864785, ENST00000864786, ENST00000864787, ENST00000864788, ENST00000864789, ENST00000864790, ENST00000864791, ENST00000864792, ENST00000864793, ENST00000864794, ENST00000864795, ENST00000864796, ENST00000864797, ENST00000864798, ENST00000912571, ENST00000912572, ENST00000912573, ENST00000912574, ENST00000912575, ENST00000912576, ENST00000912577, ENST00000912578, ENST00000952458, ENST00000952459, ENST00000952460, ENST00000952461

RefSeq mRNA: 4 — MANE Select: NM_000181 NM_000181, NM_001284290, NM_001293104, NM_001293105

CCDS: CCDS5530, CCDS64665

Canonical transcript exons

ENST00000304895 — 12 exons

Exon	Start	End
ENSE00001131491	65960684	65961063
ENSE00001554367	65981974	65982213
ENSE00003467512	65974526	65974704
ENSE00003502074	65970282	65970366
ENSE00003534535	65979727	65979911
ENSE00003569314	65967731	65967907
ENSE00003569679	65976015	65976202
ENSE00003607665	65979399	65979541
ENSE00003630799	65974295	65974441
ENSE00003638618	65974919	65975071
ENSE00003683385	65964323	65964458
ENSE00003687473	65980224	65980409

Expression profiles

Bgee: expression breadth ubiquitous, 297 present calls, max score 98.96.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 28.3209 / max 245.7589, expressed in 1812 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
84213	25.4000	1808
84212	1.9217	1035
84211	0.8995	527
84210	0.0997	24

Top tissues by expression

299 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endometrium epithelium	UBERON:0004811	98.96	gold quality
tendon of biceps brachii	UBERON:0008188	98.75	gold quality
tibia	UBERON:0000979	98.38	gold quality
visceral pleura	UBERON:0002401	97.62	gold quality
pleura	UBERON:0000977	96.66	gold quality
parietal pleura	UBERON:0002400	96.56	gold quality
trabecular bone tissue	UBERON:0002483	96.17	gold quality
palpebral conjunctiva	UBERON:0001812	96.15	gold quality
right lobe of liver	UBERON:0001114	96.11	gold quality
granulocyte	CL:0000094	96.03	gold quality
layer of synovial tissue	UBERON:0007616	95.93	gold quality
spleen	UBERON:0002106	95.85	gold quality
liver	UBERON:0002107	95.82	gold quality
placenta	UBERON:0001987	95.62	gold quality
parotid gland	UBERON:0001831	95.60	gold quality
eye	UBERON:0000970	95.57	gold quality
rectum	UBERON:0001052	95.55	gold quality
ileal mucosa	UBERON:0000331	95.52	gold quality
pylorus	UBERON:0001166	95.17	gold quality
monocyte	CL:0000576	95.15	gold quality
colonic mucosa	UBERON:0000317	95.15	gold quality
synovial joint	UBERON:0002217	95.15	gold quality
mucosa of transverse colon	UBERON:0004991	95.14	gold quality
mucosa of sigmoid colon	UBERON:0004993	95.14	gold quality
mononuclear cell	CL:0000842	95.07	gold quality
periodontal ligament	UBERON:0008266	95.04	gold quality
leukocyte	CL:0000738	95.03	gold quality
renal glomerulus	UBERON:0000074	95.00	gold quality
right lung	UBERON:0002167	94.98	gold quality
metanephric glomerulus	UBERON:0004736	94.91	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-MTAB-7303	no	895.60
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ERF, NR1I2, NR4A3, TFAP2A, VSX2

miRNA regulators (miRDB)

7 targeting GUSB, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-4255	99.72	67.70	1541
HSA-MIR-4527	99.66	67.43	714
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-6503-5P	99.62	66.96	597
HSA-MIR-6071	99.16	67.77	1780
HSA-MIR-6889-5P	90.26	64.13	291

Functional genomics

ClinGen dosage: haploinsufficiency 30 (autosomal recessive), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 19)

• beta-glucuronidase mutations are associated with mucopolysaccharidosis type VII (PMID:12522561)
• Recombinant adeno-associated virus encoding human GUSB injected into the vitreous humor of young adult MPS VII mice increased GUSB activity and reduced lysosomal distension in regions of the thalamus and tectum (PMID:12716937)
• beta glucuronidase present in the synovial fluid of rheumatoid arthritis patients, may contribute to the depletion of glycosaminoglycans from cartilage allowing invasion of synovial cells. (PMID:12905469)
• Over-expression of beta-glucuronidase was related to the degree of cancer differentiation, but not to lymph node metastasis. (PMID:14612292)
• These results indicate that beta-glucuronidase transport into brain parenchyma in early postnatal life is mediated by the mannose 6-phosphate/insulin-like growth factor II receptor. (PMID:15314220)
• The genes GUS and PMM1 are recommended for normalization purposes in gene expression studies of liver tissue from patients with chronic hepatitis. (PMID:18591914)
• Study summarized information on the 49 unique, disease-causing mutations determined so far in the GUS gene. (PMID:19224584)
• Liver disease affects the expression of common HKGs; beta-glucuronidase and splicing factor arginine/serine-rich 4 are the most stable HKGs for studies of gene expression in HCV-infected human liver. (PMID:21073651)
• GUSB and ATP2B4 have been validated as a reliable gene combination for Cystic Fibrosis Transmembrane Conductance Regulator gene qPCR data normalization. (PMID:22525089)
• This assessment demonstrated that although butyrate dramatically increased beta-glucuronidase production in bioreactors, it adversely impacted the mannose-6-phosphorylation of this lysosomal storage diseasestherapeutic enzyme (PMID:24033810)
• expression of CES2, UGTA1A1, and GUSB varies in colorectal pathology tissues and that the expression of CES2 is somewhat related to tumor staging. (PMID:24195516)
• the efficacy of a helper-dependent (HD) canine adenovirus (CAV-2) vector harboring a human GUSB expression cassette (HD-RIGIE) in the MPS VII dog brain was tested (PMID:24343103)
• the use of in silico approaches provided a useful understanding of the effect of single point mutations on the structure-function relationship of GUSBp (PMID:26415878)
• Selective and amplified bG expression together with the prodrug DOXGA3 had an increased antitumor effect, showing great potential for prostate cancer therapy. (PMID:26648021)
• Results show that GUS mRNA changes in blood are significantly correlated with gait step length variability in premutation (PM) females patients with fragile X tremor ataxia syndrome . (PMID:27387142)
• We produced GUS from a CHO cell line grown in suspension in a 15 L perfused bioreactor and developed a three step purification procedure that yields approximately 99% pure enzyme with a recovery of more than 40%. (PMID:28734840)
• the beta-d-galactosidase, beta-d-glucuronidase and alpha-l-fucosidase activities in serums from hemolyzed blood, were determined. (PMID:29885630)
• Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma. (PMID:35812439)
• Macrophages and derived-TNF-alpha promote lipopolysaccharide-induced upregulation of endogenous beta-glucuronidase in the epithelial cells of the bile duct: A possible facilitator of hepatolithiasis formation. (PMID:36473630)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	gusb	ENSDARG00000063126
mus_musculus	Gusb	ENSMUSG00000025534
rattus_norvegicus	Gusb	ENSRNOG00000000913
drosophila_melanogaster	CG15117	FBGN0034417
drosophila_melanogaster	betaGlu	FBGN0270927
caenorhabditis_elegans	Y105E8B.9	WBGENE00013693

Paralogs (1): MANBA (ENSG00000109323)

Protein

Protein identifiers

Beta-glucuronidase — P08236 (reviewed: P08236)

Alternative names: Beta-G1

All UniProt accessions (3): P08236, F2Z3L6, F8WBK6

UniProt curated annotations — full annotation on UniProt →

Function. Plays an important role in the degradation of dermatan and keratan sulfates.

Subunit / interactions. Homotetramer.

Subcellular location. Lysosome.

Post-translational modifications. N-linked glycosylated with 3 to 4 oligosaccharide chains.

Disease relevance. Mucopolysaccharidosis 7 (MPS7) [MIM:253220] A form of mucopolysaccharidosis, a group of lysosomal storage diseases characterized by defective degradation of glycosaminoglycans, resulting in their excessive accumulation and secretion. The diseases are progressive and often display a wide spectrum of clinical severity. MPS7 is an autosomal recessive form with a highly variable phenotype, ranging from severe lethal hydrops fetalis to mild forms with survival into adulthood. Most patients with the intermediate phenotype show hepatomegaly, skeletal anomalies, coarse facies, and variable degrees of mental impairment. The disease is caused by variants affecting the gene represented in this entry.

Activity regulation. Inhibited by L-aspartic acid.

Similarity. Belongs to the glycosyl hydrolase 2 family.

Isoforms (3)

UniProt ID	Names	Canonical?
P08236-1	1, Long	yes
P08236-2	2, Short
P08236-3	3

RefSeq proteins (4): NP_000172, NP_001271219, NP_001280033, NP_001280034 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006101	Glyco_hydro_2	Family
IPR006102	Ig-like_GH2	Domain
IPR006103	Glyco_hydro_2_cat	Domain
IPR006104	Glyco_hydro_2_N	Domain
IPR008979	Galactose-bd-like_sf	Homologous_superfamily
IPR013783	Ig-like_fold	Homologous_superfamily
IPR017853	GH_hydrolase_sf	Homologous_superfamily
IPR023230	Glyco_hydro_2_CS	Conserved_site
IPR023232	Glyco_hydro_2_AS	Active_site
IPR036156	Beta-gal/glucu_dom_sf	Homologous_superfamily

Pfam: PF00703, PF02836, PF02837

Enzyme classification (BRENDA):

• EC 3.2.1.31 — beta-glucuronidase (BRENDA: 70 organisms, 139 substrates, 75 inhibitors, 71 Km, 35 kcat entries)

Substrate kinetics (BRENDA)

33 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
GLYCYRRHIZIN	0.78–7.72	9
4-METHYLUMBELLIFERYL-BETA-D-GLUCURONIDE	1.04–2.76	7
4-NITROPHENYL BETA-D-GLUCURONIDE	0.0046–0.36	5
GLYCYRRHETINIC ACID 3-O-MONO-BETA-D-GLUCURONIDE	0.91–1.1	4
4-NITROPHENYL BETA-D-GLUCOSIDE	0.0304–145	3
4-NITROPHENYL-BETA-D-GLUCURONIDE	0.208–1.4	3
4-METHYLUMBELLIFERYL BETA-D-GLUCURONIDE	0.54–0.58	2
GLCABETA(1-6)GAL	0.378–0.422	2
P-NITROPHENYL-BETA-D-GLUCURONIDE	0.22–0.23	2
1-DEOXY-1-(6-THIOPURINYL)-BETA-D-GLUCOPYRANOSIDE	1.49	1
1-DEOXY-1-(6-THIOPURINYL)-BETA-D-GLUCOPYRANOSIDU	9.25	1
4-ME-BETA-GLCA-(1-6)-BETA-GAL-(1-6)-BETA-GAL-(1-	1.4	1
4-ME-BETA-GLCA-(1-6)-BETA-GAL-(1-6)-GAL	1.9	1
4-ME-BETA-GLCA-(1-6)-GAL	3.6	1
4-METHYLUMBELLIFERYL-BETA-D-GLUCURONIC ACID	1.25	1

Catalyzed reactions (Rhea), 1 shown:

• a beta-D-glucuronoside + H2O = D-glucuronate + an alcohol (RHEA:17633)

UniProt features (108 total): sequence variant 40, strand 36, helix 16, turn 7, glycosylation site 4, splice variant 2, signal peptide 1, chain 1, active site 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
3HN3	X-RAY DIFFRACTION	1.7
1BHG	X-RAY DIFFRACTION	2.53

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P08236-F1	94.35	0.93

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 451 (proton donor)

Glycosylation sites (4): 173, 272, 420, 631

Function

Pathways and Gene Ontology

Reactome pathways

17 pathways

ID	Pathway
R-HSA-2024101	CS/DS degradation
R-HSA-2160916	Hyaluronan degradation
R-HSA-2206292	MPS VII - Sly syndrome (Hyaluronan metabolism)
R-HSA-6798695	Neutrophil degranulation
R-HSA-9953080	MPS VII - Sly syndrome (CS/DS degradation)
R-HSA-1430728	Metabolism
R-HSA-1630316	Glycosaminoglycan metabolism
R-HSA-1638091	Heparan sulfate/heparin (HS-GAG) metabolism
R-HSA-1643685	Disease
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System
R-HSA-2024096	HS-GAG degradation
R-HSA-2142845	Hyaluronan metabolism
R-HSA-2206281	Mucopolysaccharidoses
R-HSA-5663084	Diseases of carbohydrate metabolism
R-HSA-5668914	Diseases of metabolism
R-HSA-71387	Metabolism of carbohydrates and carbohydrate derivatives

MSigDB gene sets: 505 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_PHOSPHATIDYLINOSITOL_METABOLIC_PROCESS, GOBP_CARTILAGE_DEVELOPMENT, GOBP_VACUOLE_ORGANIZATION, GOBP_SKELETAL_SYSTEM_DEVELOPMENT, GOBP_INFLAMMATORY_RESPONSE, PAL_PRMT5_TARGETS_UP, GOCC_SECRETORY_GRANULE, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, GOBP_GROWTH

GO Biological Process (35): retinoid metabolic process (GO:0001523), in utero embryonic development (GO:0001701), endochondral ossification (GO:0001958), muscle system process (GO:0003012), chondrocyte hypertrophy (GO:0003415), growth plate cartilage morphogenesis (GO:0003422), carbohydrate metabolic process (GO:0005975), glycosaminoglycan catabolic process (GO:0006027), autophagy (GO:0006914), inflammatory response (GO:0006954), lysosome organization (GO:0007040), cell population proliferation (GO:0008283), protein secretion (GO:0009306), gene expression (GO:0010467), heparan sulfate proteoglycan catabolic process (GO:0030200), chondroitin sulfate proteoglycan catabolic process (GO:0030207), hyaluronan catabolic process (GO:0030214), protein localization to nucleus (GO:0034504), multicellular organism growth (GO:0035264), aorta development (GO:0035904), phosphatidylinositol-3-phosphate biosynthetic process (GO:0036092), TORC1 signaling (GO:0038202), response to peptide hormone (GO:0043434), bone resorption (GO:0045453), homeostasis of number of cells (GO:0048872), articular cartilage development (GO:0061975), energy homeostasis (GO:0097009), cranial skeletal system development (GO:1904888), skeletal system development (GO:0001501), ossification (GO:0001503), growth plate cartilage development (GO:0003417), protein catabolic process (GO:0030163), bone development (GO:0060348), bone morphogenesis (GO:0060349), bone growth (GO:0098868)

GO Molecular Function (7): beta-glucuronidase activity (GO:0004566), signaling receptor binding (GO:0005102), protein domain specific binding (GO:0019904), carbohydrate binding (GO:0030246), hydrolase activity, hydrolyzing O-glycosyl compounds (GO:0004553), hydrolase activity (GO:0016787), hydrolase activity, acting on glycosyl bonds (GO:0016798)

GO Cellular Component (9): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), endoplasmic reticulum (GO:0005783), membrane (GO:0016020), azurophil granule lumen (GO:0035578), lysosomal lumen (GO:0043202), extracellular exosome (GO:0070062), ficolin-1-rich granule lumen (GO:1904813), lysosome (GO:0005764)

Reactome top-level categories

Rollup of top-12 pathways:

Category	Pathways
Mucopolysaccharidoses	2
Glycosaminoglycan metabolism	2
Chondroitin sulfate/dermatan sulfate metabolism	1
Hyaluronan metabolism	1
Innate Immune System	1
Metabolism of carbohydrates and carbohydrate derivatives	1
Immune System	1
Heparan sulfate/heparin (HS-GAG) metabolism	1
Diseases of carbohydrate metabolism	1
Diseases of metabolism	1
Disease	1
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
proteoglycan catabolic process	2
protein binding	2
cellular anatomical structure	2
vacuolar lumen	2
diterpenoid metabolic process	1
chordate embryonic development	1
replacement ossification	1
endochondral bone morphogenesis	1
system process	1
chondrocyte development	1
developmental cell growth	1
growth plate cartilage development	1
cartilage morphogenesis	1
primary metabolic process	1
aminoglycan catabolic process	1
glycosaminoglycan metabolic process	1
catabolic process	1
transmembrane transport	1
process utilizing autophagic mechanism	1
defense response	1
lytic vacuole organization	1
cellular process	1
protein transport	1
secretion by cell	1
establishment of protein localization to extracellular region	1
protein localization to extracellular region	1
macromolecule biosynthetic process	1
heparan sulfate proteoglycan metabolic process	1
chondroitin sulfate proteoglycan metabolic process	1
glycosaminoglycan catabolic process	1
hyaluronan metabolic process	1
protein localization to organelle	1
multicellular organismal process	1
developmental growth	1
artery development	1
glucuronidase activity	1
binding	1
hydrolase activity, acting on glycosyl bonds	1
catalytic activity	1
hydrolase activity	1

Protein interactions and networks

STRING

3476 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GUSB	KL	Q9UEF7	869
GUSB	ARSA	P15289	838
GUSB	OGA	O60502	830
GUSB	GAPDH	P00354	766
GUSB	MPI	P34949	758
GUSB	CES1	P23141	756
GUSB	IGF2R	P11717	744
GUSB	TRPV5	Q9NQA5	741
GUSB	HPRT1	P00492	735
GUSB	B2M	P01884	733
GUSB	ARSB	P15848	729
GUSB	MPO	P05164	728
GUSB	POTEF	A5A3E0	718
GUSB	IDUA	P35475	717
GUSB	TBP	P20226	715

IntAct

95 interactions, top by confidence:

A	B	Type	Score
CDK4	HSP90AA1	psi-mi:“MI:0914”(association)	0.640
CANX	PGRMC1	psi-mi:“MI:0914”(association)	0.570
GUSB		psi-mi:“MI:0915”(physical association)	0.550
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
ZBTB42	MID1	psi-mi:“MI:0914”(association)	0.530
ADAMTS4	MANBA	psi-mi:“MI:0914”(association)	0.530
C1orf54	EXTL3	psi-mi:“MI:0914”(association)	0.530
CDK4	GUSB	psi-mi:“MI:0914”(association)	0.530
DNAJC3	DEDD	psi-mi:“MI:0914”(association)	0.530
GUSB	BRAF	psi-mi:“MI:2364”(proximity)	0.470
BRAF	GUSB	psi-mi:“MI:0915”(physical association)	0.470
GUSB	GUSB	psi-mi:“MI:0407”(direct interaction)	0.440
VRK1	GUSB	psi-mi:“MI:0915”(physical association)	0.400
GUSB	GIT2	psi-mi:“MI:0915”(physical association)	0.370
HSCB	RBP5	psi-mi:“MI:0914”(association)	0.350
FBXO6	GNS	psi-mi:“MI:0914”(association)	0.350
	DENND11	psi-mi:“MI:0914”(association)	0.350
	VPS37C	psi-mi:“MI:0914”(association)	0.350
	P4HA2	psi-mi:“MI:0914”(association)	0.350
MFAP4	CRLF1	psi-mi:“MI:0914”(association)	0.350
SCGB2A2	RTL8C	psi-mi:“MI:0914”(association)	0.350
CEACAM8	PRRT4	psi-mi:“MI:0914”(association)	0.350
SLURP1	MANBA	psi-mi:“MI:0914”(association)	0.350
TMEM25	NME4	psi-mi:“MI:0914”(association)	0.350
GUSB	HOXA3	psi-mi:“MI:0914”(association)	0.350
IDS	COCH	psi-mi:“MI:0914”(association)	0.350
BTNL2	TMEM131L	psi-mi:“MI:0914”(association)	0.350

BioGRID (88): GUSB (Affinity Capture-MS), GUSB (Affinity Capture-MS), GUSB (Affinity Capture-MS), GUSB (Affinity Capture-MS), FAHD1 (Co-fractionation), HOXA3 (Affinity Capture-MS), PMEL (Affinity Capture-MS), GUSB (Affinity Capture-MS), GUSB (Affinity Capture-MS), GUSB (Affinity Capture-MS), GUSB (Affinity Capture-MS), GUSB (Affinity Capture-MS), GUSB (Affinity Capture-MS), CES1 (Affinity Capture-Western), GUSB (Proximity Label-MS)

ESM2 similar proteins: A0JMP0, A4IG42, A5PJN5, A6QLU7, A6QQ07, F1N2K1, O00462, O18835, O43280, O77695, O95479, O97524, P08236, P10253, P12265, P19813, P70699, P82450, Q3U4H6, Q4FAT7, Q4FZV0, Q5E985, Q5FVF9, Q5R5N6, Q5R7A9, Q5R8R3, Q5RFU0, Q5XHI4, Q641Z7, Q6P6V7, Q6P7A9, Q6QR59, Q6RHW4, Q76HN1, Q865R1, Q8BFW6, Q8BNE1, Q8BP56, Q8C0L6, Q8CFX1

Diamond homologs: A0A089LCJ8, O18835, O77695, O97524, P05804, P06760, P08236, P12265, Q4FAT7, Q5R5N6, Q6P575, Q8E0N2, Q8XP19, Q15486, P06219, Q9K9C6, A6T8X0, A7LXS9, B5XQY2, Q56307

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
TFEB	“up-regulates quantity by expression”	GUSB	“transcriptional regulation”
ACSS2	“up-regulates quantity by expression”	GUSB	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

771 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	55
Likely pathogenic	40
Uncertain significance	221
Likely benign	369
Benign	20

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
100722	NM_000181.4(GUSB):c.530C>T (p.Thr177Ile)	Pathogenic
1027384	NM_000181.4(GUSB):c.1651C>T (p.Gln551Ter)	Pathogenic
2087077	NM_000181.4(GUSB):c.932dup (p.Ser312fs)	Pathogenic
2111403	NM_000181.4(GUSB):c.24del (p.Trp9fs)	Pathogenic
2117122	NM_000181.4(GUSB):c.604C>T (p.Gln202Ter)	Pathogenic
2231212	NM_000181.4(GUSB):c.1583G>A (p.Trp528Ter)	Pathogenic
2431204	NM_000181.4(GUSB):c.1874del (p.Arg625fs)	Pathogenic
2431211	NM_000181.4(GUSB):c.7del (p.Arg3fs)	Pathogenic
2698405	NM_000181.4(GUSB):c.867_871del (p.Trp289_Tyr291delinsTer)	Pathogenic
2701335	NM_000181.4(GUSB):c.643C>T (p.Gln215Ter)	Pathogenic
2728754	NM_000181.4(GUSB):c.74dup (p.Gly26fs)	Pathogenic
2731024	NM_000181.4(GUSB):c.1455dup (p.Asn486Ter)	Pathogenic
2735027	NM_000181.4(GUSB):c.1457_1460del (p.Asn486fs)	Pathogenic
2736760	NM_000181.4(GUSB):c.1047del (p.Asn349fs)	Pathogenic
2755268	NM_000181.4(GUSB):c.190del (p.Tyr64fs)	Pathogenic
2757736	NM_000181.4(GUSB):c.1809dup (p.Asn604fs)	Pathogenic
2766408	NM_000181.4(GUSB):c.1872_1875dup (p.Tyr626fs)	Pathogenic
2797791	NM_000181.4(GUSB):c.320del (p.Leu107fs)	Pathogenic
2799488	NM_000181.4(GUSB):c.916C>T (p.Gln306Ter)	Pathogenic
2803581	NM_000181.4(GUSB):c.739C>T (p.Gln247Ter)	Pathogenic
2806625	NM_000181.4(GUSB):c.11_12del (p.Gly4fs)	Pathogenic
2841797	NM_000181.4(GUSB):c.76_79dup (p.Met27fs)	Pathogenic
2847045	NM_000181.4(GUSB):c.1865T>A (p.Leu622Ter)	Pathogenic
2848108	NC_000007.14:g.65974442del	Pathogenic
2852702	NM_000181.4(GUSB):c.325G>T (p.Glu109Ter)	Pathogenic
2863642	NM_000181.4(GUSB):c.507dup (p.Ile170fs)	Pathogenic
2867424	NM_000181.4(GUSB):c.1872_1875del (p.Glu624fs)	Pathogenic
2869792	NM_000181.4(GUSB):c.527_530del (p.Leu176fs)	Pathogenic
2891880	NM_000181.4(GUSB):c.434del (p.Gly145fs)	Pathogenic
2903068	NM_000181.4(GUSB):c.1756dup (p.Ile586fs)	Pathogenic

SpliceAI

2134 predictions. Top by Δscore:

Variant	Effect	Δscore
7:65961059:CGGTG:C	acceptor_gain	1.0000
7:65961061:GTGC:G	acceptor_loss	1.0000
7:65961062:TGC:T	acceptor_loss	1.0000
7:65961063:GC:G	acceptor_loss	1.0000
7:65961064:C:CC	acceptor_gain	1.0000
7:65964318:CTTAC:C	donor_loss	1.0000
7:65964320:TACAC:T	donor_loss	1.0000
7:65964321:A:AC	donor_gain	1.0000
7:65964322:C:CC	donor_gain	1.0000
7:65964322:CA:C	donor_gain	1.0000
7:65964322:CACT:C	donor_gain	1.0000
7:65964322:CACTG:C	donor_gain	1.0000
7:65964454:GGATC:G	acceptor_gain	1.0000
7:65964455:GATC:G	acceptor_gain	1.0000
7:65964456:ATC:A	acceptor_gain	1.0000
7:65964457:TC:T	acceptor_gain	1.0000
7:65964458:CC:C	acceptor_gain	1.0000
7:65964459:C:CC	acceptor_gain	1.0000
7:65964459:C:T	acceptor_gain	1.0000
7:65964464:A:AC	acceptor_gain	1.0000
7:65964467:C:CT	acceptor_gain	1.0000
7:65964468:A:T	acceptor_gain	1.0000
7:65964472:C:CT	acceptor_gain	1.0000
7:65964473:A:T	acceptor_gain	1.0000
7:65967729:A:AT	donor_loss	1.0000
7:65974292:CACTT:C	donor_loss	1.0000
7:65974293:A:AC	donor_gain	1.0000
7:65974293:A:C	donor_loss	1.0000
7:65974293:ACTT:A	donor_gain	1.0000
7:65974294:C:CC	donor_gain	1.0000

AlphaMissense

4252 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:65964353:A:G	W587R	0.998
7:65964353:A:T	W587R	0.998
7:65974350:A:G	W446R	0.998
7:65974350:A:T	W446R	0.998
7:65974618:G:C	S384R	0.997
7:65974618:G:T	S384R	0.997
7:65974620:T:G	S384R	0.997
7:65961014:T:A	R613S	0.996
7:65961014:T:G	R613S	0.996
7:65961015:C:G	R613T	0.996
7:65961034:C:A	G607W	0.996
7:65961034:C:G	G607R	0.996
7:65961034:C:T	G607R	0.996
7:65964336:G:C	F592L	0.996
7:65964336:G:T	F592L	0.996
7:65964338:A:G	F592L	0.996
7:65974553:T:A	E406V	0.996
7:65974625:C:G	R382P	0.996
7:65974626:G:T	R382S	0.996
7:65967767:G:C	S539R	0.995
7:65967767:G:T	S539R	0.995
7:65967769:T:G	S539R	0.995
7:65974617:G:C	H385D	0.995
7:65974664:T:G	D369A	0.995
7:65974665:C:G	D369H	0.995
7:65974927:C:G	D353H	0.995
7:65976065:A:G	W288R	0.995
7:65976065:A:T	W288R	0.995
7:65979499:A:C	F208L	0.995
7:65979499:A:T	F208L	0.995

dbSNP variants (sampled 300 via entrez): RS1000541273 (7:65962076 T>A), RS1000786397 (7:65983479 G>A), RS1000862844 (7:65978424 G>T), RS1000889798 (7:65977854 A>C), RS1000944410 (7:65983048 G>C), RS1001242154 (7:65962480 G>A,T), RS1001242776 (7:65962807 G>C), RS1001551410 (7:65978000 C>T), RS1001662167 (7:65977874 A>G), RS1001705711 (7:65969555 G>A), RS1001820487 (7:65983286 C>A), RS1001950098 (7:65981780 T>C), RS1002042558 (7:65971174 G>A), RS1002061277 (7:65979048 C>A), RS1002151006 (7:65976880 G>A,T)

Disease associations

OMIM: gene MIM:611499 | disease phenotypes: MIM:253220, MIM:236750, MIM:253200

GenCC curated gene-disease

Disease	Classification	Inheritance
mucopolysaccharidosis type 7	Definitive	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
mucopolysaccharidosis type 7	Definitive	AR

Mondo (5): mucopolysaccharidosis type 7 (MONDO:0009662), prostate cancer (MONDO:0008315), non-immune hydrops fetalis (MONDO:0009369), intellectual disability (MONDO:0001071), mucopolysaccharidosis type 6 (MONDO:0009661)

Orphanet (5): Mucopolysaccharidosis type 7 (Orphanet:584), Familial prostate cancer (Orphanet:1331), Non-immune hydrops fetalis (Orphanet:363999), Mucopolysaccharidosis type 6 (Orphanet:583), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

82 total (30 of 82 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000023	Inguinal hernia
HP:0000158	Macroglossia
HP:0000212	Gingival overgrowth
HP:0000238	Hydrocephalus
HP:0000256	Macrocephaly
HP:0000280	Coarse facial features
HP:0000286	Epicanthus
HP:0000324	Facial asymmetry
HP:0000365	Hearing impairment
HP:0000403	Recurrent otitis media
HP:0000407	Sensorineural hearing impairment
HP:0000470	Short neck
HP:0000505	Visual impairment
HP:0000574	Thick eyebrow
HP:0000613	Photophobia
HP:0000687	Widely spaced teeth
HP:0000767	Pectus excavatum
HP:0000768	Pectus carinatum
HP:0000926	Platyspondyly
HP:0000943	Dysostosis multiplex
HP:0001004	Lymphedema
HP:0001007	Hirsutism
HP:0001249	Intellectual disability
HP:0001252	Hypotonia
HP:0001270	Motor delay
HP:0001371	Flexion contracture
HP:0001376	Limitation of joint mobility
HP:0001387	Joint stiffness
HP:0001537	Umbilical hernia

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST90013406_127	Liver enzyme levels (alkaline phosphatase)	3.000000e-15

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004533	alkaline phosphatase measurement

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D009087	Mucopolysaccharidosis VI	C16.320.565.202.715.670; C16.320.565.595.600.670; C17.300.550.575.670; C18.452.648.202.715.670; C18.452.648.595.600.670
D016538	Mucopolysaccharidosis VII	C16.320.565.202.715.675; C16.320.565.595.600.675; C17.300.550.575.675; C18.452.648.202.715.675; C18.452.648.595.600.675
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2728 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 49,362 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL90593	PRASTERONE	4	23,422
CHEMBL150	KAEMPFEROL	1	25,940

PharmGKB: 1 entry (VIP=true, CPIC=false)

Binding affinities (BindingDB)

117 measured of 155 human assays (157 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
4-chloro-N-[(4-chlorophenyl)methyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	30 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-[(3-methylphenyl)methyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	30 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-[(2-chlorophenyl)methyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	40 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-[(3-fluorophenyl)methyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	40 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-(3-methoxyphenyl)-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	70 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-(3-chlorophenyl)-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	70 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-[(3-chlorophenyl)methyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	90 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-(naphthalen-1-ylmethyl)-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	90 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
N-(naphthalen-1-ylmethyl)-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	90 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-[(4-methoxyphenyl)methyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	100 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
5-(3-piperazin-1-ylphenoxy)-N-(2-pyrrolidin-1-ylethyl)thiophene-2-sulfonamide	IC50	120 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-methyl-N-(naphthalen-1-ylmethyl)-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	120 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-[(3,5-dichlorophenyl)methyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	130 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
N-[3-(dimethylamino)propyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	150 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-(4-methoxyphenyl)-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	170 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-[2-(3,4-dimethoxyphenyl)ethyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	190 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
N-[2-(N-ethyl-3-methylanilino)ethyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	200 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
N-[(2-bromophenyl)methyl]-4-chloro-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	210 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
N-[(2,4-dimethylphenyl)methyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	210 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
N-(1,3-benzodioxol-5-ylmethyl)-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	220 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
N-(4-methoxyphenyl)-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	230 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
N-[2-(4-chlorophenyl)ethyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	240 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-[2-(2-fluorophenyl)ethyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	270 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
N-(cyclohexylmethyl)-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	270 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
N-benzyl-4-chloro-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	280 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
N-[(3,4-dimethoxyphenyl)methyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	290 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-5-(3-piperazin-1-ylphenoxy)-N-[[3-(trifluoromethyl)phenyl]methyl]thiophene-2-sulfonamide	IC50	290 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-(naphthalen-1-ylmethyl)-5-(4-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	300 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-[(3,5-dimethoxyphenyl)methyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	310 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
N-[3-(2-oxopyrrolidin-1-yl)propyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	320 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
N-(1,3-benzodioxol-5-ylmethyl)-4-chloro-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	320 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
N-[2-(2-fluorophenyl)ethyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	330 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	330 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-[(3,4-dimethoxyphenyl)methyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	340 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-[(3-methoxyphenyl)methyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	350 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
N-(3-methylsulfanylpropyl)-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	390 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-[(2,4-dimethylphenyl)methyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	410 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-(4-phenylbutan-2-yl)-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	430 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
(E)-5-chloro-N’-(2,4,5-trihydroxybenzylidene)-1H-indole-2-carbohydrazide (10)	IC50	500 nM
4-chloro-N-[2-(4-chlorophenyl)ethyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	500 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-cyclopentyl-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	510 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
N-[2-(4-methoxyphenyl)ethyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	510 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
N-cycloheptyl-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	560 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
N-[(3-methoxyphenyl)methyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	570 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
5-(3-piperazin-1-ylphenoxy)-N-(thiophen-2-ylmethyl)thiophene-2-sulfonamide	IC50	600 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
5-(3-piperazin-1-ylphenoxy)-N-(2-thiophen-2-ylethyl)thiophene-2-sulfonamide	IC50	630 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-(oxolan-2-ylmethyl)-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	710 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
4-chloro-N-[3-(2-oxopyrrolidin-1-yl)propyl]-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	730 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
ethyl 4-[[5-(3-piperazin-1-ylphenoxy)thiophen-2-yl]sulfonylamino]piperidine-1-carboxylate	IC50	730 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase
N-cyclohexyl-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	IC50	750 nM	US-9617239: Phenoxy thiophene sulfonamides and their use as inhibitors of glucuronidase

ChEMBL bioactivities

278 potent at pChembl≥5 of 416 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.01	IC50	0.984	nM	CHEMBL3980115
8.93	IC50	1.17	nM	CHEMBL3980115
8.47	EC50	3.41	nM	CHEMBL3980115
8.45	EC50	3.58	nM	CHEMBL3980115
8.10	IC50	8	nM	CHEMBL5409470
8.01	IC50	9.75	nM	CHEMBL5273557
7.75	EC50	17.7	nM	CHEMBL3903683
7.70	IC50	20	nM	CHEMBL4635113
7.55	EC50	28.3	nM	CHEMBL1236932
7.54	EC50	29	nM	CHEMBL3903683
7.52	IC50	30	nM	CHEMBL4635884
7.52	IC50	30	nM	CHEMBL4633508
7.48	EC50	33.2	nM	CHEMBL1236932
7.40	IC50	40	nM	CHEMBL4649028
7.40	IC50	40	nM	CHEMBL4647420
7.16	IC50	70	nM	CHEMBL3289121
7.16	IC50	70	nM	CHEMBL5863393
7.16	IC50	70	nM	CHEMBL5915942
7.05	IC50	90	nM	CHEMBL4648659
7.05	IC50	90	nM	CHEMBL4635113
7.05	IC50	90	nM	CHEMBL4634028
7.03	EC50	92.4	nM	CHEMBL2335167
7.00	EC50	99.9	nM	CHEMBL2335167
7.00	IC50	100	nM	CHEMBL4165927
7.00	IC50	100	nM	CHEMBL4168635
7.00	IC50	100	nM	CHEMBL4642327
7.00	IC50	100	nM	CHEMBL4644220
6.93	IC50	118	nM	CHEMBL4642420
6.92	IC50	120	nM	CHEMBL4632976
6.92	IC50	120	nM	CHEMBL6014082
6.92	IC50	120	nM	CHEMBL4642704
6.89	IC50	130	nM	CHEMBL4643487
6.85	IC50	142	nM	CHEMBL4641808
6.82	IC50	150	nM	CHEMBL5950647
6.77	IC50	170	nM	CHEMBL5965722
6.72	IC50	190	nM	CHEMBL5864563
6.70	IC50	200	nM	CHEMBL4177204
6.70	IC50	200	nM	CHEMBL4643914
6.70	IC50	200	nM	CHEMBL5840028
6.68	IC50	210	nM	CHEMBL5992833
6.68	IC50	210	nM	CHEMBL5953913
6.67	IC50	212.6	nM	CHEMBL2335167
6.66	EC50	221.2	nM	CHEMBL1236933
6.66	IC50	220	nM	CHEMBL5907131
6.64	IC50	230.6	nM	CHEMBL2335167
6.64	IC50	230	nM	CHEMBL5866010
6.63	EC50	233.2	nM	CHEMBL1236933
6.62	IC50	240	nM	CHEMBL6031655
6.57	IC50	270	nM	CHEMBL5928918
6.57	IC50	270	nM	CHEMBL5956299

PubChem BioAssay actives

201 with measured affinity, of 502 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-(13-piperazin-1-yl-11-thia-9,14,15,16-tetrazatetracyclo[8.7.0.02,7.012,17]heptadeca-1(10),2(7),8,12(17),13,15-hexaen-8-yl)morpholine	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	0.0012	uM
(5S,6R,7S,8S)-6,7,8-trihydroxy-2-[2-(3-phenoxyphenyl)ethyl]-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-5-carboxylic acid	2018409: Inhibition of recombinant human GUSbeta using 4-MUG as substrate pre-incubated for 10 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.0080	uM
(5S,6R,7S,8S)-6,7,8-trihydroxy-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-5-carboxylic acid	1922231: Inhibition of human beta-glucuronidase	ic50	0.0097	uM
4-chloro-N-(naphthalen-1-ylmethyl)-5-(3-piperazin-1-ylphenoxy)thiophene-2-sulfonamide	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	0.0200	uM
2-(2-ethoxyphenyl)-3H-quinazolin-4-one	1656455: Inhibition of beta-glucuronidase (unknown origin) using p-nitrophenyl-beta-d-glucuronide as substrate after 30 mins	ic50	0.0700	uM
1-[[4-[bis(1H-indol-3-yl)methyl]benzoyl]amino]-3-(2-fluorophenyl)thiourea	1656455: Inhibition of beta-glucuronidase (unknown origin) using p-nitrophenyl-beta-d-glucuronide as substrate after 30 mins	ic50	0.1000	uM
N-[(E)-(2,3-dihydroxyphenyl)methylideneamino]-3-[[5-[[(E)-(2,3-dihydroxyphenyl)methylideneamino]carbamoyl]-1H-indol-3-yl]-(4-methylphenyl)methyl]-1H-indole-5-carboxamide	1494144: Inhibition of human beta-glucuronidase	ic50	0.1000	uM
3-[(4-methylphenyl)-[5-[[(E)-(2,4,5-trihydroxyphenyl)methylideneamino]carbamoyl]-1H-indol-3-yl]methyl]-N-[(E)-(2,4,5-trihydroxyphenyl)methylideneamino]-1H-indole-5-carboxamide	1494144: Inhibition of human beta-glucuronidase	ic50	0.1000	uM
1-[(6,8-dimethyl-2-oxo-1H-quinolin-3-yl)methyl]-1-(2-hydroxyethyl)-3-(2-methylphenyl)urea	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	0.1180	uM
1-[[4-[bis(1H-indol-3-yl)methyl]benzoyl]amino]-3-(3,4-dichlorophenyl)thiourea	1801941: β-Glucuronidase Bioassay from Article 10.1016/j.bioorg.2016.07.008: “Synthesis, ß-glucuronidase inhibition and molecular docking studies of hybrid bisindole-thiosemicarbazides analogs.”	ic50	0.1200	uM
1-[[4-[bis(1H-indol-3-yl)methyl]benzoyl]amino]-3-[4-(trifluoromethyl)phenyl]thiourea	1656455: Inhibition of beta-glucuronidase (unknown origin) using p-nitrophenyl-beta-d-glucuronide as substrate after 30 mins	ic50	0.1200	uM
1-[(6,8-dimethyl-2-oxo-1H-quinolin-3-yl)methyl]-3-(4-fluoro-2-methylphenyl)-1-(2-hydroxyethyl)urea	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	0.1420	uM
3-[(4-methylphenyl)-[5-[[(E)-(2,4,6-trihydroxyphenyl)methylideneamino]carbamoyl]-1H-indol-3-yl]methyl]-N-[(E)-(2,4,6-trihydroxyphenyl)methylideneamino]-1H-indole-5-carboxamide	1494144: Inhibition of human beta-glucuronidase	ic50	0.2000	uM
1-[(6,8-dimethyl-2-oxo-1H-quinolin-3-yl)methyl]-3-(4-ethoxyphenyl)-1-(2-hydroxyethyl)thiourea	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	0.2800	uM
N-[(E)-(3,4-dihydroxyphenyl)methylideneamino]-3-[[5-[[(E)-(3,4-dihydroxyphenyl)methylideneamino]carbamoyl]-1H-indol-3-yl]-(4-methylphenyl)methyl]-1H-indole-5-carboxamide	1494144: Inhibition of human beta-glucuronidase	ic50	0.3000	uM
N-[(E)-(2,4-dihydroxyphenyl)methylideneamino]-3-[[5-[[(E)-(2,4-dihydroxyphenyl)methylideneamino]carbamoyl]-1H-indol-3-yl]-(4-methylphenyl)methyl]-1H-indole-5-carboxamide	1494144: Inhibition of human beta-glucuronidase	ic50	0.3000	uM
3-(2-bromophenyl)-1-[(6,8-dimethyl-2-oxo-1H-quinolin-3-yl)methyl]-1-(2-hydroxyethyl)urea	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	0.3470	uM
N,N-diethyl-6-methyl-2-sulfanylidene-4-thiophen-2-yl-3,4-dihydro-1H-pyrimidine-5-carboxamide	1667339: Inhibition of beta-glucuronidase (unknown origin) using p-nitrophenyl-beta-D-glucuronide as substrate pre-incubated for 30 mins followed by substrate addition by spectrophotometric method	ic50	0.3500	uM
1-[(6,8-dimethyl-2-oxo-1H-quinolin-3-yl)methyl]-1-(2-hydroxyethyl)-3-(4-methoxyphenyl)thiourea	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	0.3700	uM
1-[(6,8-dimethyl-2-oxo-1H-quinolin-3-yl)methyl]-1-(2-hydroxyethyl)-3-(2-propan-2-ylphenyl)urea	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	0.4680	uM
1-[[4-[bis(1H-indol-3-yl)methyl]benzoyl]amino]-3-(2-chlorophenyl)thiourea	1656455: Inhibition of beta-glucuronidase (unknown origin) using p-nitrophenyl-beta-d-glucuronide as substrate after 30 mins	ic50	0.5000	uM
5-chloro-N-[(E)-(2,4,5-trihydroxyphenyl)methylideneamino]-1H-indole-2-carboxamide	1656455: Inhibition of beta-glucuronidase (unknown origin) using p-nitrophenyl-beta-d-glucuronide as substrate after 30 mins	ic50	0.5000	uM
3-[5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-yl]benzene-1,2-diol	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	0.5000	uM
2,7-dimethyl-4-piperazin-1-yl-4b,5,6,7,8,8a-hexahydro-[1]benzothiolo[2,3-d]pyrimidine	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	0.5400	uM
9-[[1-(pyridin-3-ylmethyl)triazol-4-yl]methyl]carbazole	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	0.5500	uM
(E)-3-(4-chlorophenyl)-1-(2,5-dihydroxyphenyl)prop-2-en-1-one	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	0.6000	uM
2-(3,4-dimethoxyphenyl)-3H-quinazolin-4-one	1153850: Inhibition of beta-glucuronidase activity (unknown origin) assessed as p-nitrophenol formation after 30 mins using p-nitrophenyl-beta-D-glucuronide as substrate by spectrophotometry	ic50	0.6000	uM
N,N-diethyl-6-methyl-4-(3-nitrophenyl)-2-sulfanylidene-3,4-dihydro-1H-pyrimidine-5-carboxamide	1667339: Inhibition of beta-glucuronidase (unknown origin) using p-nitrophenyl-beta-D-glucuronide as substrate pre-incubated for 30 mins followed by substrate addition by spectrophotometric method	ic50	0.6000	uM
N,N-diethyl-4-(3-hydroxyphenyl)-6-methyl-2-sulfanylidene-3,4-dihydro-1H-pyrimidine-5-carboxamide	1667339: Inhibition of beta-glucuronidase (unknown origin) using p-nitrophenyl-beta-D-glucuronide as substrate pre-incubated for 30 mins followed by substrate addition by spectrophotometric method	ic50	0.7200	uM
1-(3-bromo-4-hydroxyphenyl)-2-[4-(carbazol-9-ylmethyl)triazol-1-yl]ethanone	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	0.7500	uM
3-(2-cyclopropylphenyl)-1-[(6,8-dimethyl-2-oxo-1H-quinolin-3-yl)methyl]-1-(2-hydroxyethyl)urea	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	0.7590	uM
4,4-dimethyl-14-sulfanylidene-5-oxa-8-thia-10,12,13,15-tetrazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2(7),10-trien-16-one	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	0.7590	uM
N,N-diethyl-4-(3-hydroxy-4-methoxyphenyl)-6-methyl-2-sulfanylidene-3,4-dihydro-1H-pyrimidine-5-carboxamide	1667339: Inhibition of beta-glucuronidase (unknown origin) using p-nitrophenyl-beta-D-glucuronide as substrate pre-incubated for 30 mins followed by substrate addition by spectrophotometric method	ic50	0.7600	uM
2-[4-[5-(2-fluorophenyl)-1,3,4-oxadiazol-2-yl]phenyl]chromen-4-one	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	0.8000	uM
(5S,6R,7R,8S)-7,8-dihydroxy-6-methoxy-2-[2-(3-phenoxyphenyl)ethyl]-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-5-carboxylic acid	2018409: Inhibition of recombinant human GUSbeta using 4-MUG as substrate pre-incubated for 10 mins followed by substrate addition and measured after 60 mins by fluorescence based assay	ic50	0.8390	uM
1-(3-bromo-4-methoxyphenyl)-2-[4-(carbazol-9-ylmethyl)triazol-1-yl]ethanone	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	0.8500	uM
(E)-4,4,4-triethoxy-1-[3-methyl-4-phenyl-5-[(E)-4,4,4-triethoxybut-2-enoyl]thieno[2,3-b]thiophen-2-yl]but-2-en-1-one	1165427: Inhibition of beta-glucuronidase (unknown origin) using p-nitrophenyl-beta-D-glucuronide substrate incubated for 30 mins by spectrophotometry	ic50	0.9000	uM
3-[5-(1H-indol-2-ylmethyl)-1,3,4-oxadiazol-2-yl]benzene-1,2-diol	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	0.9000	uM
3-methoxy-4-[5-[4-[5-(2,4,6-trichlorophenyl)-1,3,4-thiadiazol-2-yl]phenyl]-1,3,4-oxadiazol-2-yl]phenol	1545107: Inhibition of human beta-glucuronidase pre-incubated for 30 mins before p-nitrophenyl-beta-D-glucuronide substrate addition by spectrophotometry	ic50	0.9600	uM
methyl 2-[[2-hydroxyethyl-[(6-methyl-2-oxo-1H-quinolin-3-yl)methyl]carbamothioyl]amino]benzoate	1656455: Inhibition of beta-glucuronidase (unknown origin) using p-nitrophenyl-beta-d-glucuronide as substrate after 30 mins	ic50	1.0600	uM
2-(4-methoxyphenyl)-3H-quinazolin-4-one	1153850: Inhibition of beta-glucuronidase activity (unknown origin) assessed as p-nitrophenol formation after 30 mins using p-nitrophenyl-beta-D-glucuronide as substrate by spectrophotometry	ic50	1.1000	uM
4-[5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-yl]benzene-1,2-diol	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	1.1000	uM
N-[(E)-(2,4-dichlorophenyl)methylideneamino]-3-[[5-[[(E)-(2,4-dichlorophenyl)methylideneamino]carbamoyl]-1H-indol-3-yl]-(4-methylphenyl)methyl]-1H-indole-5-carboxamide	1494144: Inhibition of human beta-glucuronidase	ic50	1.1000	uM
2-[4-[5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl]phenyl]chromen-4-one	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	1.1000	uM
N-[(E)-(2,5-dihydroxyphenyl)methylideneamino]-3-[[5-[[(E)-(2,5-dihydroxyphenyl)methylideneamino]carbamoyl]-1H-indol-3-yl]-(4-methylphenyl)methyl]-1H-indole-5-carboxamide	1494144: Inhibition of human beta-glucuronidase	ic50	1.1400	uM
2-(3-ethoxy-4-hydroxyphenyl)-3H-quinazolin-4-one	1153850: Inhibition of beta-glucuronidase activity (unknown origin) assessed as p-nitrophenol formation after 30 mins using p-nitrophenyl-beta-D-glucuronide as substrate by spectrophotometry	ic50	1.1700	uM
2-(2-methyl-5-nitroimidazol-1-yl)ethyl 2-chloro-4,5-difluorobenzoate	1667338: Inhibition of beta-glucuronidase (unknown origin)	ic50	1.2000	uM
N-[(E)-(2-fluorophenyl)methylideneamino]-3-[[5-[[(E)-(2-fluorophenyl)methylideneamino]carbamoyl]-1H-indol-3-yl]-(4-methylphenyl)methyl]-1H-indole-5-carboxamide	1494144: Inhibition of human beta-glucuronidase	ic50	1.2000	uM
3-[(5-bromo-1H-indol-3-yl)-(6-bromo-1H-indol-3-yl)methyl]benzene-1,2-diol	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	1.2000	uM
4-[5-(1H-indol-2-ylmethyl)-1,3,4-oxadiazol-2-yl]benzene-1,2-diol	1656436: Inhibition of beta-glucuronidase (unknown origin)	ic50	1.2000	uM

CTD chemical–gene interactions

48 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases expression, affects cotreatment	3
sodium arsenite	increases abundance, affects expression, decreases expression	3
Ozone	increases oxidation, increases abundance, affects expression, affects cotreatment, increases expression	3
Valproic Acid	increases expression, increases methylation	3
methacrylaldehyde	affects cotreatment, increases expression, increases oxidation, increases abundance	2
epigallocatechin gallate	increases secretion, affects cotreatment, increases expression, decreases reaction	2
Acetaminophen	increases expression	2
Acrolein	affects cotreatment, increases expression, increases oxidation, increases abundance	2
Air Pollutants	increases oxidation, affects expression, affects cotreatment, increases abundance, increases expression	2
Benzo(a)pyrene	decreases methylation, affects reaction, increases expression, increases reaction	2
Doxorubicin	decreases expression, affects response to substance	2
bisphenol F	increases expression	1
PF-06840003	decreases expression, decreases reaction	1
ginger extract	increases abundance, increases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases expression, increases oxidation, increases abundance	1
benoxaprofen	increases secretion	1
potassium chromate(VI)	affects cotreatment, increases expression	1
mannose-6-phosphate	affects reaction, increases expression	1
Am 580	increases expression	1
6-((2-(4-imidazolyl)ethyl)amino)heptanoic acid 4-toluidide	increases expression, increases reaction	1
fexofenadine	affects binding, decreases reaction, increases activity, increases expression	1
ICG 001	increases expression	1
bisphenol B	increases expression	1
jinfukang	increases expression	1
picoxystrobin	increases expression	1
bisphenol AF	increases expression	1
Rosiglitazone	increases expression	1
Sunitinib	decreases expression	1
Arsenic	decreases expression, increases abundance	1

ChEMBL screening assays

41 unique, capped per target: 38 binding, 3 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1071205	Binding	Inhibition of beta-glucuronidase at 10 uM	Synthesis and biological evaluation of nitrogen-containing chalcones as possible anti-inflammatory and antioxidant agents. — Bioorg Med Chem Lett
CHEMBL4026921	ADMET	Inhibition of N-terminal His-tagged human beta-glucuronidase expressed in Escherichia coli BL21 (DE3) assessed as residual activity using pNPG as substrate at 10 uM preincubated for 30 mins followed by substrate addition measured after 1 hr	Specific Inhibition of Bacterial β-Glucuronidase by Pyrazolo[4,3-c]quinoline Derivatives via a pH-Dependent Manner To Suppress Chemotherapy-Induced Intestinal Toxicity. — J Med Chem

Cellosaurus cell lines

9 cell lines: 6 cancer cell line, 3 finite cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_0P00	GM02074	Finite cell line	Female
CVCL_D1MZ	Abcam K-562 GUSB KO	Cancer cell line	Female
CVCL_D2JJ	Abcam Raji GUSB KO	Cancer cell line	Male
CVCL_D5ET	HeLa::TMEM192-3xHA GUSB KO	Cancer cell line	Female
CVCL_M988	GM01850	Finite cell line	Male
CVCL_SQ73	HAP1 GUSB (-) 1	Cancer cell line	Male
CVCL_SQ74	HAP1 GUSB (-) 2	Cancer cell line	Male
CVCL_UQ66	Abcam Jurkat GUSB KO	Cancer cell line	Male
CVCL_V751	GM00121	Finite cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer